The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Open accessAbstract
A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Aβ binds to α7 nicotinic acetylcholine receptors (α7 nAChRs) and to metabotropic glutamate receptors, in particular mGluR5 [31–33].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [33]
In the citing paper
“A genome-wide association study (GWAS) identified PrPC as a potential high-affinity receptor for oAβ [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“Subsequent studies showed that oAβ, especially high-molecular weight oligomers [88], preferentially bind to PrPC within an N-terminal 95-111aa segment [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“oligomer binding is significantly reduced in PrPC knock-out cells (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“PrPC binds synthetic Aβ oligomers with high affinity and plays a role in the oligomer-mediated inhibition of LTP (17).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“In an elegant study Lauren et al. (17) reported that PrPC mediates the Aβ oligomer-induced hippocampal synaptic plasticity impairment.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“The 22 °C-Aβ oligomers impaired recognition memory in both Prnp +/+ and Prnp 0/0 mice (Fig. 4C).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“When amyloid-β oligomers bind to PrPc, long-term potentiation and the formation of new memories are disrupted [129,130,131].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,678
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Rescuing neurons in prion disease
Verity, N., & Mallucci, G. R. (2010) · Biochemical Journal · doi:10.1042/bj20101323 · Cited by 19
Interactions of Aromatic Residues in Amyloids: A Survey of Protein Data Bank Crystallographic Data
Stanković, I. M., Bozinovski, D. M., Brothers, E. N., Belić, M. R., Hall, M. B., & Zarić, S. D. (2017) · Crystal Growth & Design · doi:10.1021/acs.cgd.7b01035 · Cited by 19
Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy
Nieznańska, H., Bandyszewska, M., Surewicz, K. A., Zajkowski, T., Surewicz, W. K., & Nieznański, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.023 · Cited by 19
A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers
Silverman, J. M., Gibbs, E., Peng, X., Martens, K. M., Balducci, C., Wang, J., Yousefi, M., Cowan, C. M., Lamour, G., Louadi, S., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00469 · Cited by 21
Takasugi, N., Araya, R., Kamikubo, Y., Kaneshiro, N., Imaoka, R., Jin, H., Kashiyama, T., Hashimoto, Y., Kurosawa, M., Uehara, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200988 · Cited by 20
Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity
Forest, K. H., & Nichols, R. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.013 · Cited by 19
PrPC as a Transducer of Physiological and Pathological Signals
Panes-Fernández, J., Saavedra, P., Pineda, B., Escobar, K., Cuevas, M. E., Moraga‐Cid, G., Fuentealba, J., Rivas, C. I., Rezaei, H., & Muñoz-Montesino, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.762918 · Cited by 20
Recent developments in the chemical biology of amyloid-β oligomer targeting
Wang, Y., Chen, J., Gao, F., Hu, M., & Wang, X. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob00509g · Cited by 20
He, J., Li, X., Yang, J., Huang, J., Fu, X., Zhang, Y., & Fan, H. X. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.01.020 · Cited by 19
Huang, F.-L., Shiao, Y., Hou, S.-J., Yang, C.-N., Chen, Y., Lin, C., Shie, F., & Tsay, H.-J. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-54 · Cited by 19
Alzheimer's disease, cellular prion protein, and dolphins
Guardo, G. D. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.12.002 · Cited by 19
Ma, L., Xiao, H., Wen, J., Liu, Z., He, Y., & Yuan, F. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0708-6 · Cited by 19
Functions of the cellular prion protein, the end of Moore's law, and Ockham's razor theory
del Rı́o, J. A., & Gavı́n, R. (2016) · Prion · doi:10.1080/19336896.2015.1126038 · Cited by 19
Overcoming barriers and thresholds – signaling of oligomeric Aβ through the prion protein to Fyn
Wang, H., Ren, C. H., Gunawardana, C. G., & Schmitt‐Ulms, G. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-24 · Cited by 18
Lymphocyte‐Activation Gene 3 Facilitates Pathological Tau Neuron‐to‐Neuron Transmission
Chen, C., Kumbhar, R., Wang, H., Yang, X., Gadhave, K., Rastegar, C. T., Kimura, Y., Behensky, A. A., Kotha, S., Kuo, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202303775 · Cited by 18
Mandino, F., Shen, X., Desrosiers-Grégoire, G., O’Connor, D. A., Mukherjee, B., Owens, A., Qu, A., Onofrey, J. A., Papademetris, X., Chakravarty, M. M., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02779-z · Cited by 19
Self-citationDametto, P., Lakkaraju, A. K., Bridel, C., Villiger, L., O’Connor, T., Herrmann, U., Pelczar, P., Rülicke, T., McHugh, D., Adili, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117412 · Cited by 18
Almost a century of prion protein(s): From pathology to physiology, and back to pathology
Peggion, C., Bertoli, A., & Sorgato, M. C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.118 · Cited by 18
Tyurikova, O., Zheng, K., Rings, A., Drews, A., Klenerman, D., & Rusakov, D. A. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.12.007 · Cited by 18
PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity
Mengel, D., Hong, W., Corbett, G. T., Liu, W., DeSousa, A., Solforosi, L., Fang, C., Frosch, M. P., Collinge, J., Harris, D. A., et al. (2018) · Brain Research · doi:10.1016/j.brainres.2018.12.038 · Cited by 18
Kong, C., Xie, H., Gao, Z., Shao, M., Li, H., Shi, R., Cai, L., Gao, S., Sun, T., & Li, C. (2019) · Virologica Sinica · doi:10.1007/s12250-019-00124-1 · Cited by 18
Posadas, Y., López-Guerrero, V. E., Segovia, J., Perez‐Cruz, C., & Quintanar, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102098 · Cited by 18
Alzheimer Disease: The Role of Aβ in the Glutamatergic System
Campos‐Peña, V., & Antônio, M. (2014) · InTech eBooks · doi:10.5772/57367 · Cited by 24
Prion protein expression alters APP cleavage without interaction with BACE-1
McHugh, P., Wright, J. A., Williams, R. J., & Brown, D. R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.07.002 · Cited by 18
Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration
Moreno, J. A., & Mallucci, G. R. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380482 · Cited by 19
The Fatal Attraction Between Pro-Prion and Filamin A: Prion As a Marker in Human Cancers
Sy, M., Li, C., Yu, S., & Xin, W. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.14 · Cited by 18
Svedružić, Ž. M., Popović, K., Smoljan, I., & Jengić, V. Š. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032293 · Cited by 18
Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity
Pagano, K., Galante, D., D’Arrigo, C., Corsaro, A., Nizzari, M., Florio, T., Molinari, H., Tomaselli, S., & Ragona, L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1202-x · Cited by 20
Homer1a and mGluR1/5 Signaling in Homeostatic Sleep Drive and Output.
Martin, S. C., Monroe, S., & Diering, G. H. (2019) · Europe PMC (PubMed Central) · Cited by 18
Wang, Y., Wang, J., Chen, X., Lin, Z., You, Z., He, K., Guo, T., Zhao, J., Huang, Q., Ni, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70004 · Cited by 17
Prions and Prion-Like Pathogens in Neurodegenerative Disorders
Peggion, C., Sorgato, M. C., & Bertoli, A. (2014) · Pathogens · doi:10.3390/pathogens3010149 · Cited by 17
Cong, X., Casiraghi, N. A., Rossetti, G., Mohanty, S., Giachin, G., Legname, G., & Carloni, P. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct400534k · Cited by 17
Amyloid Oligomer Structures and Toxicity
Glabe, C. G. (2009) · The Open Biology Journal · doi:10.2174/1874196700902010222 · Cited by 18
Natale, G. D., Turi, I., Pappalardo, G., Sóvágó, I., & Rizzarelli, E. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201405502 · Cited by 17
Stocki, P., Sawicki, M., Mays, C. E., Hong, S. J., Chapman, D. C., Westaway, D. A., & Williams, D. B. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-10-0729 · Cited by 21
Jeon, Y., Lee, S., Shin, M., Lee, J. H., Suh, Y. S., Hwang, S., Yun, H. S., & Cho, K. S. (2017) · Animal Cells and Systems · doi:10.1080/19768354.2017.1313777 · Cited by 17
Yamada, S., & Sakakibara, S. (2018) · The Journal of Comparative Neurology · doi:10.1002/cne.24495 · Cited by 17
Vascular and non‐vascular contributors to memory reduction during traumatic brain injury
Charkviani, M., Muradashvili, N., & Lominadze, D. G. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14390 · Cited by 17
The Membrane Axis of Alzheimer's Nanomedicine
Li, Y., Tang, H., Andrikopoulos, N., Javed, I., Cecchetto, L., Nandakumar, A., Käkinen, A., Davis, T. P., Ding, F., & Ke, P. C. (2020) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000040 · Cited by 17
Poejo, J., Salazar, J., Mata, A. M., & Gutiérrez‐Merino, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041984 · Cited by 17
Zhang, X., Zou, L. B., Meng, L., Xiong, M., Pan, L., Chen, G., Zheng, Y., Xiong, J., Wang, Z., Duong, D. M., et al. (2021) · eLife · doi:10.7554/elife.65301 · Cited by 17
Vascular Effects on Cerebrovascular Permeability and Neurodegeneration
Sulimai, N., Brown, J. D., & Lominadze, D. G. (2023) · Biomolecules · doi:10.3390/biom13040648 · Cited by 17
Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology
Tannenberg, R. K., Shamaileh, H. A., Lauridsen, L. H., Kanwar, J. R., Dodd, P. R., & Veedu, R. N. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310040009 · Cited by 17
Xing, Y., & Xia, N. (2014) · Analytical Letters · doi:10.1080/00032719.2014.968925 · Cited by 17
Honda, R. P. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201800197 · Cited by 18
Ishizawa, K., Mitsufuji, T., Shioda, K., Kobayashi, A., Komori, T., Nakazato, Y., Kitamoto, T., Araki, N., Yamamoto, T., & Sasaki, A. (2018) · Brain and Behavior · doi:10.1002/brb3.1117 · Cited by 17
Tau oligomers impair memory and synaptic plasticity through the cellular prion protein
Balducci, C., Orsini, F., Cerovic, M., Beeg, M., Rocutto, B., Dacomo, L., Masone, A., Busani, E., Raimondi, I., Lavigna, G., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01930-3 · Cited by 16
Alzheimer's disease/dementia-associated brain pathology in aging DPP6-KO mice
Lin, L., Petralia, R. S., Holtzclaw, L. A., Wang, Y., Abebe, D. T., & Hoffman, D. A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105887 · Cited by 17
A systemic analysis of Creutzfeldt Jakob disease cases in Asia
Rasheed, U., Khan, S. I., Khalid, M., Noor, A., & Zafar, S. (2024) · Prion · doi:10.1080/19336896.2024.2311950 · Cited by 16
Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid β Peptide
Uranga, R. M., Alza, N. P., Conde, M. A., Antollini, S. S., & Salvador, G. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9885-3 · Cited by 16
Goñi, F., Martá-Ariza, M., Peyser, D. K., Herline, K., & Wısnıewskı, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-10393-z · Cited by 16
Intertwined Pathologies of Amyloid-β and Metal Ions in Alzheimer’s Disease: Metal–Amyloid-β
Nam, G., & Lim, M. H. (2019) · Chemistry Letters · doi:10.1246/cl.190281 · Cited by 16
Esparza, T. J., Gangolli, M., Cairns, N. J., & Brody, D. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200251 · Cited by 16
Boswellic Acids as Promising Leads in Drug Development against Alzheimer’s Disease
Haghaei, H., Soltani, S., Hosseini, S. R. A., Rashidi, M., & Karima, S. (2020) · Pharmaceutical Sciences · doi:10.34172/ps.2020.25 · Cited by 16
Muradashvili, N., Charkviani, M., Sulimai, N., Tyagi, N., Crosby, J. R., & Lominadze, D. G. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147208 · Cited by 16
Kedikian, G., Heredia, F., Rozés‐Salvador, V., Raimunda, D., Isoardi, N. A., Heredia, L., & Lorenzo, A. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22347 · Cited by 17
Prion protein (PrP) gene-knockout cell lines: insight into functions of the PrP
Sakudo, A., & Onodera, T. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00075 · Cited by 16
Polajnar, M., Čeru, S., Kopitar‐Jerala, N., & Žerovnik, E. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00088 · Cited by 16
Role of prions in neuroprotection and neurodegeneration
Zamponi, G. W., & Stys, P. K. (2009) · Prion · doi:10.4161/pri.3.4.9549 · Cited by 16
Torrent, J., Vílchez-Acosta, A., Muñoz‐Torrero, D., Trovaslet, M., Nachon, F., Chatonnet, A., Grznárová, K., Ba, I. A.-T. V., Goffic, R. L., Herzog, L., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0188-0 · Cited by 16
Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrPC
Corda, E., Du, X., Shim, S. Y., Klein, A. N., Siltberg-Liberles, J., & Gilch, S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0944-9 · Cited by 16
Zhang, L., Ma, Q., Yang, W., Qi, X., Yao, Z., Liu, Y., Liang, L., Wang, X., Ma, C., Huang, L., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.023 · Cited by 15
Dagla, I., Gkikas, F., Gikas, E. E., & Tsarbopoulos, A. (2026) · Cells · doi:10.3390/cells15030295 · Cited by 16
Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 16
Varges, D., Jung, K., Gawinecka, J., Heinemann, U., Schmitz, M., von Ahsen, N., Krasnianski, A., Armstrong, V. W., & Zerr, I. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101527 · Cited by 15
Aberrant ERK 1/2 complex activation and localization in scrapie-infected GT1-1 cells
Didonna, A., & Legname, G. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-29 · Cited by 15
Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats
Zhang, J., Wei, S.-Y., Yuan, L., Kong, L., Zhang, S., Wang, Z., Wu, M., & Qi, J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.038 · Cited by 15
Allison, W. T., DuVal, M. G., Nguyen-Phuoc, K., & Leighton, P. L. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102223 · Cited by 17
Nieznańska, H., Boyko, S., Dec, R., Rędowicz, M. J., Dzwolak, W., & Nieznański, K. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166209 · Cited by 16
Mohammadi, B., Song, F., Matamoros‐Angles, A., Shafiq, M., Daμμe, M., Puig, B., Glatzel, M., & Altmeppen, H. C. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03582-4 · Cited by 15
Lewis, V., Whitehouse, I. J., Baybutt, H. N., Manson, J. C., Collins, S. J., & Hooper, N. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031754 · Cited by 15
Mendola, D. L., & Rizzarelli, E. (2014) · Biomolecules · doi:10.3390/biom4020546 · Cited by 15
Psychotropic Drug Effects on Gene Transcriptomics Relevant to Alzheimer Disease
Lauterbach, E. C. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318214b7d0 · Cited by 15
Suzuki, K., Aimi, T., Ishihara, T., & Mizushima, T. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12056 · Cited by 16
The Level of NMDA Receptor in the Membrane Modulates Amyloid-β Association and Perforation
Peters, C., Sepúlveda, F. J., Fernández-Pérez, E. J., Peoples, R. W., & Aguayo, L. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160170 · Cited by 15
Shedding light on aberrant interactions – a review of modern tools for studying protein aggregates
Kundel, F., Tosatto, L., Whiten, D. R., Wirthensohn, D. C., Horrocks, M. H., & Klenerman, D. (2018) · FEBS Journal · doi:10.1111/febs.14409 · Cited by 16
Yuen, S. C., Zhu, H., & Leung, S.-W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00209 · Cited by 16
The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers
Stravalaci, M., Tapella, L., Beeg, M., Rossi, A., Joshi, P., Pizzi, E., Mazzanti, M., Balducci, C., Forloni, G., Biasini, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150882 · Cited by 15
Mouillet-Richard, S., Martin-Lannerée, S., Le Corre, D., Hirsch, T. Z., Ghazi, A., Sroussi, M., Pilati, C., de Reyniès, A., Djouadi, F., Vodovar, N., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02430-7 · Cited by 14
Advancing Nanomaterial-Based Strategies for Alzheimer’s Disease: A Perspective
Zhou, H., Yin, X., Zhang, G., Yang, Z., & Zhou, R. (2025) · JACS Au · doi:10.1021/jacsau.5c00002 · Cited by 15
Dextran sulfate sodium inhibits amyloid‐β oligomer binding to cellular prion protein
Aimi, T., Suzuki, K., Hoshino, T., & Mizushima, T. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13166 · Cited by 14
Gug, F., Oumata, N., Tribouillard‐Tanvier, D., Voisset, C., Desban, N., Bach, S., Blondel, M., & Galons, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900314n · Cited by 14
Proteomic profiling of cerebrospinal fluid in Creutzfeldt–Jakob disease
Qualtieri, A., Urso, E., Pera, M. L., Sprovieri, T., Bossio, S., Gambardella, A., & Quattrone, A. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.80 · Cited by 14
Jackson, W. S., Krost, C., Borkowski, A. W., & Kaczmarczyk, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095958 · Cited by 14
Yagi, H., Takeuchi, H., Ogawa, S., Ito, N., Sakane, I., Hongo, K., Mizobata, T., Goto, Y., & Kawata, Y. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.07.007 · Cited by 14
Using small molecule reagents to selectively modify epitopes based on their conformation
Silva, C. J. (2012) · Prion · doi:10.4161/pri.18795 · Cited by 14
Pretreatment of chemically-synthesized Aβ42affects its biological activity in yeast
Porzoor, A., Caine, J. M., & Macreadie, I. G. (2014) · Prion · doi:10.4161/19336896.2014.992275 · Cited by 14
CSF prion protein concentration and cognition in patients with Alzheimer disease
Schmidt, C., Artjomova, S., Hoeschel, M., & Zerr, I. (2013) · Prion · doi:10.4161/pri.23904 · Cited by 14
Involvement of ‘stress–response’ kinase pathways in Alzheimer's disease progression
Mairet‐Coello, G., & Polleux, F. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.03.011 · Cited by 16
A current view of Alzheimer's disease
Hooli, B. V., & Tanzi, R. E. (2009) · F1000 Biology Reports · doi:10.3410/b1-54 · Cited by 14
Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Chiarini, A., Gardenal, E., Whitfield, J., Chakravarthy, B., Armato, U., & Prà, I. D. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505123813 · Cited by 14
Soluble Aβ aggregates can inhibit prion propagation
Sarell, C. J., Quarterman, E., Yip, D. C.-M., Terry, C., Nicoll, A. J., Wadsworth, J. D. F., Farrow, M. A., Walsh, D. M., & Collinge, J. (2017) · Open Biology · doi:10.1098/rsob.170158 · Cited by 14
Cetaceans, models for human disease?
Guardo, G. D. (2018) · Research in Veterinary Science · doi:10.1016/j.rvsc.2018.05.012 · Cited by 14
Peggion, C., Stella, R., Chemello, F., Massimino, M. L., Arrigoni, G., Cagnin, S., Biancotto, G., Franchin, C., Sorgato, M. C., & Bertoli, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1293-4 · Cited by 14
Advances in Detection Methods of β-Amyloid Protein
Jiang, M., Wang, X., & Wang, X. (2018) · Chinese Journal of Analytical Chemistry · doi:10.1016/s1872-2040(18)61107-7 · Cited by 14
Kanyo, R., Leighton, P. L. A., Neil, G. J., Locskai, L. F., & Allison, W. T. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113283 · Cited by 14
HIV-1 and Amyloid Beta Remodel Proteome of Brain Endothelial Extracellular Vesicles
Andras, I. E., Sewell, B., & Toborek, M. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082741 · Cited by 14
Schneider, B., Baudry, A., Pietri, M., Alleaume‐Butaux, A., Bizingre, C., Nioche, P., Kellermann, O., & Launay, J. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.660683 · Cited by 15
Cade, S., Zhou, X., & Bobrovskaya, L. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0111 · Cited by 14
Boumedine, N., & Bouroubi, S. (2022) · Applied Soft Computing · doi:10.1016/j.asoc.2022.108564 · Cited by 14
Metadata
- Authors
- Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- Venue
- Nature
- Published
- 2009-02
- Volume
- 457
- Issue
- 7233
- Pages
- 1128-1132
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2748841
- OpenAlex
- W2171526610
- Cited by
- 1,560
- References
- 37
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 50 · 2023: 52 · 2022: 87 · 2021: 82 · 2020: 85 · 2019: 71 · 2018: 108 · 2017: 117 · 2016: 103 · 2015: 98 · 2014: 104 · 2013: 116 · 2012: 119
- FWCI
- 87.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (5T32GN07205)
- National Institute on Drug Abuse (P30DA018343)
- National Institute of Neurological Disorders and Stroke (R01NS042304, R01NS039962, R37NS033020)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cellular prion protein, amyloid-beta oligomers, Alzheimer's disease, synaptic plasticity, long-term potentiation, cell surface receptors, lipid rafts, hippocampus, anti-PrP antibodies, prion disease, expression cloning, neurotoxicity, spatial memory, neuroprotection, neurodegeneration
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Chlorocebus aethiops, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Neurons, Peptide Fragments, Prions, Protein Binding, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Long-Term Potentiation, COS Cells, Mice, Amyloid Precursor Protein Secretases, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
